<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04179058</url>
  </required_header>
  <id_info>
    <org_study_id>2019PI251</org_study_id>
    <nct_id>NCT04179058</nct_id>
  </id_info>
  <brief_title>Interstitial Pneumonia With Autoimmune Features: Evaluation of Connective Tissue Disease Incidence During Follow-up</brief_title>
  <acronym>EVOLIPAF</acronym>
  <official_title>Interstitial Pneumonia With Autoimmune Features: Evaluation of Connective Tissue Disease Incidence During Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interstitial lung diseases (ILD) represent a frequent complication of connective tissue
      diseases (CTDs), especially systemic sclerosis, idiopathic inflammatory myopathies and
      rheumatoid arthritis. ILD can either occur during CTD course or be the first manifestation of
      CTDs. Therefore screening patients with ILD for CTD is crucial. In some cases, ILD are
      associated with clinical and/or serological autoimmune features but not classifiable for
      CTDs. Evolution of these forms to defined CTDs has never been study. Recently, the European
      Respiratory Society/American Thoracic Society experts proposed a new term, &quot;interstitial
      pneumonia with autoimmune features&quot; or IPAF, to describe these patients according to updated
      classification criteria. Aims of this study were to compare CTD occurence during follow-up
      between IPAF and non-IPAF patients in a idiopathic interstitial pneumonia cohort and to
      identify risk factors of CTD progression in IPAF patients at diagnosis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CTD incidence</measure>
    <time_frame>After 3 years of follow-up</time_frame>
    <description>CTD incidence according to classification criteria: rheumatoid arthritis (2010 ACR/EULAR criteria), systemic erythematosus lupus (2019 ACR/EULAR criteria), Sjögren syndrome (2016 ACR/EULAR criteria), systemic sclerosis (2013 ACR/EULAR criteria), idiopathic inflammatory myopathies (2017 ACR/EULAR criteria) and mixed connective tissue disease (modified Sharp criteria or Alarcon-Segovia criteria or Kasukawa criteria)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IPAF clinical domain criteria</measure>
    <time_frame>Baseline</time_frame>
    <description>&quot;mechanic hands&quot;, Gottron's sign, distal digital tip ulceration, inflammatory arthritis or polyarticular joint stiffness &gt; 60mn, telangiectasia, Raynaud's phenomenon, unexplained digital oedema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IPAF serological domain criteria</measure>
    <time_frame>Baseline</time_frame>
    <description>ANA titre and pattern, RF, anti-CCP, anti-dsDNA, anti-Ro, anti-La, anti-ribonucleoprotein, anti-Smith, anti-Scl70, anti-tRNA synthetase, anti-PM-Scl, anti-MDA5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IPAF morphological domain criteria</measure>
    <time_frame>Baseline</time_frame>
    <description>NSIP, and/or OP, or LIP radiology pattern by HRCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ILD severity</measure>
    <time_frame>Baseline, 6 months of follow-up and at the last visit</time_frame>
    <description>PFT (pulmonary function test): FVC, FEV1, DLCO (percentages of predicted values)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rate</measure>
    <time_frame>After 3 years and 5 years of follow-up</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Idiopathic Interstitial Pneumonia</condition>
  <arm_group>
    <arm_group_label>IPAF patients</arm_group_label>
    <description>IPAF definition according to 2015 ERS/ATS criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-IPAF patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Follow-up</intervention_name>
    <description>Clinical data, radiological data and laboratory tests follow-up</description>
    <arm_group_label>IPAF patients</arm_group_label>
    <arm_group_label>non-IPAF patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with idiopathic interstitial pneumonia classifiable or not as IPAF
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a new diagnosis of ILD confirmed by two chest-HRCT 3 months apart

          -  Patients with a minimal follow-up duration of 3 years after ILD diagnosis

        Exclusion Criteria:

          -  Patients with a defined CTD at ILD diagnosis

          -  Patients with an other ILD etiology identified at diagnosis (i.e. sarcoidosis,
             hypersensitivity pneumonitis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roland JAUSSAUD, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Hospital, Nancy, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roland JAUSSAUD, Pr</last_name>
    <phone>0383154067</phone>
    <email>r.jaussaud@chru-nancy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul DECKER, MR</last_name>
    <email>p.decker@chru-nancy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Central Hospital</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Hospital</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Roland JAUSSAUD, Pr</last_name>
      <email>r.jaussaud@chru-nancy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Paul DECKER, MR</last_name>
      <email>p.decker@chru-nancy.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007 Jul;66(7):940-4. Epub 2007 Feb 28.</citation>
    <PMID>17329309</PMID>
  </reference>
  <reference>
    <citation>Fathi M, Dastmalchi M, Rasmussen E, Lundberg IE, Tornling G. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis. 2004 Mar;63(3):297-301.</citation>
    <PMID>14962966</PMID>
  </reference>
  <reference>
    <citation>Tanaka N, Kim JS, Newell JD, Brown KK, Cool CD, Meehan R, Emoto T, Matsumoto T, Lynch DA. Rheumatoid arthritis-related lung diseases: CT findings. Radiology. 2004 Jul;232(1):81-91. Epub 2004 May 27.</citation>
    <PMID>15166329</PMID>
  </reference>
  <reference>
    <citation>Keane MP, Lynch JP 3rd. Pleuropulmonary manifestations of systemic lupus erythematosus. Thorax. 2000 Feb;55(2):159-66. Review.</citation>
    <PMID>10639536</PMID>
  </reference>
  <reference>
    <citation>Tillie-Leblond I, Wislez M, Valeyre D, Crestani B, Rabbat A, Israel-Biet D, Humbert M, Couderc LJ, Wallaert B, Cadranel J. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax. 2008 Jan;63(1):53-9. Epub 2007 Jun 8.</citation>
    <PMID>17557770</PMID>
  </reference>
  <reference>
    <citation>Kinder BW, Collard HR, Koth L, Daikh DI, Wolters PJ, Elicker B, Jones KD, King TE Jr. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med. 2007 Oct 1;176(7):691-7. Epub 2007 Jun 7.</citation>
    <PMID>17556720</PMID>
  </reference>
  <reference>
    <citation>Vij R, Noth I, Strek ME. Autoimmune-featured interstitial lung disease: a distinct entity. Chest. 2011 Nov;140(5):1292-1299. doi: 10.1378/chest.10-2662. Epub 2011 May 12.</citation>
    <PMID>21565966</PMID>
  </reference>
  <reference>
    <citation>Fischer A, West SG, Swigris JJ, Brown KK, du Bois RM. Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest. 2010 Aug;138(2):251-6. doi: 10.1378/chest.10-0194.</citation>
    <PMID>20682528</PMID>
  </reference>
  <reference>
    <citation>Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, Lee JS, Leslie KO, Lynch DA, Matteson EL, Mosca M, Noth I, Richeldi L, Strek ME, Swigris JJ, Wells AU, West SG, Collard HR, Cottin V; “ERS/ATS Task Force on Undifferentiated Forms of CTD-ILD”. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015 Oct;46(4):976-87. doi: 10.1183/13993003.00150-2015. Epub 2015 Jul 9.</citation>
    <PMID>26160873</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 18, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Connective tissue disease</keyword>
  <keyword>Interstitial lung disease</keyword>
  <keyword>Interstitial pneumonia with autoimmune features</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
    <mesh_term>Connective Tissue Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

